CDC vaccine committee votes unanimously to recommend Sanofi and AstraZeneca's RSV immunization for babies
The CDC’s vaccine advisory committee unanimously recommended Sanofi’s RSV shot for babies on Thursday. Newborns and infants under 8 months of age should receive the Beyfortus (nirsevimab) monoclonal antibody in advance of the RSV season, the Advisory Committee on Immunization Practices (ACIP) announced after a 10-0 vote.
The committee also recommended Beyfortus immunizations for children aged 8 to 19 months who are at higher risk for RSV and going into a second season, by the same 10-0 vote. The RSV season typically begins in November and runs for five months through March.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.